Diabetic Macular Edema – Companies Involved in Therapeutics Development Abpro,Aciont Inc,Acucela Inc,Aerie Pharmaceuticals

Diabetic Macular Edema
Diabetic macular edema (DME) occurs when blood vessels in the retina of patients with diabetes begin to leak into the macula, the part of the eye responsible for detailed central vision. Common symptoms of DME are blurry vision, floaters, double vision, and eventually blindness if it goes untreated. Risk factors include age and diabetes.

A new independent 231 page research with title ‘Diabetic Macular Edema – Pipeline Review, H2 2018’ guarantees you will remain better informed than your competition. The study covers geographic analysis that includes regions and important players/vendors such as Abpro,Aciont Inc,Acucela Inc,Aerie Pharmaceuticals With n-number of tables and figures examining the Diabetic Macular Edema the research gives you a visual, one-stop breakdown of the leading products, submarkets and market leader’s market revenue forecasts as well as analysis to 2022

 

Request a sample report @ https://www.htfmarketreport.com/sample-report/1262575-diabetic-macular-edema-pipeline-review-4

 

HTF latest Pharmaceutical and Healthcare disease pipeline guide Diabetic Macular Edema – Pipeline Review, H2 2018, provides an overview of the Diabetic Macular Edema (Metabolic Disorders) pipeline landscape.

 

 

Report Highlights

HTF Pharmaceutical and Healthcare latest pipeline guide Diabetic Macular Edema – Pipeline Review, H2 2018, provides comprehensive information on the therapeutics under development for Diabetic Macular Edema (Metabolic Disorders), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

 

Get customization & check discount for report @ https://www.htfmarketreport.com/request-discount/1262575-diabetic-macular-edema-pipeline-review-4

 

 

The Diabetic Macular Edema (Metabolic Disorders) pipeline guide also reviews of key players involved in therapeutic development for Diabetic Macular Edema and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Pre-Registration, Phase III, Phase II, Phase I, IND/CTA Filed, Preclinical and Discovery stages are 1, 5, 19, 7, 2, 35 and 4 respectively. Similarly, the Universities portfolio in Preclinical and Discovery stages comprises 2 and 1 molecules, respectively.

                                                        

Diabetic Macular Edema (Metabolic Disorders) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from HTF proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Scope

 

– The pipeline guide provides a snapshot of the global therapeutic landscape of Diabetic Macular Edema (Metabolic Disorders).

– The pipeline guide reviews pipeline therapeutics for Diabetic Macular Edema (Metabolic Disorders) by companies and universities/research institutes based on information derived from company and industry-specific sources.

– The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.

– The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.

– The pipeline guide reviews key companies involved in Diabetic Macular Edema (Metabolic Disorders) therapeutics and enlists all their major and minor projects.

– The pipeline guide evaluates Diabetic Macular Edema (Metabolic Disorders) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.

– The pipeline guide encapsulates all the dormant and discontinued pipeline projects.

– The pipeline guide reviews latest news related to pipeline therapeutics for Diabetic Macular Edema (Metabolic Disorders)

 

Reasons to buy

 

– Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.

– Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.

– Find and recognize significant and varied types of therapeutics under development for Diabetic Macular Edema (Metabolic Disorders).

– Classify potential new clients or partners in the target demographic.

– Develop tactical initiatives by understanding the focus areas of leading companies.

– Plan mergers and acquisitions meritoriously by identifying key players and it’s most promising pipeline therapeutics.

– Formulate corrective measures for pipeline projects by understanding Diabetic Macular Edema (Metabolic Disorders) pipeline depth and focus of Indication therapeutics.

– Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.

– Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.

 

View Detailed Table of Content @ https://www.htfmarketreport.com/reports/1262575-diabetic-macular-edema-pipeline-review-4

 

Companies Mentioned in the Report: Abpro,Aciont Inc,Acucela Inc,Aerie Pharmaceuticals Inc,Aldeyra Therapeutics Inc,Allergan Plc,Allgenesis Biotherapeutics Inc,Ampio Pharmaceuticals Inc,Araim Pharmaceuticals Inc,Boehringer Ingelheim GmbH,Cell Medica Ltd,Celon Pharma SA,Chengdu Kanghong Pharmaceuticals Group Co Ltd,Clearside BioMedical Inc,Coherus BioSciences Inc,Daiichi Sankyo Co Ltd,Elasmogen Ltd,Exonate Ltd,EyeGate Pharmaceuticals Inc,EyePoint Pharmaceuticals Inc,Eyevensys SAS,F. Hoffmann-La Roche Ltd,Formycon AG,Gene Signal International SA,Genmab A/S,Graybug Vision Inc,Isarna Therapeutics GmbH,Kalvista Pharmaceuticals Inc,Kowa Co Ltd,Lupin Ltd,Mabion SA,Momenta Pharmaceuticals Inc,Novartis AG,Ocular Therapeutix Inc,Oculis ehf,OcuNexus Therapeutics Inc,Ohr Pharmaceutical Inc,Pfizer Inc,Profarma,Protheragen Inc,Regeneron Pharmaceuticals Inc,Rezolute Inc,SciFluor Life Sciences LLC,Senju Pharmaceutical Co Ltd,Stealth BioTherapeutics Inc,ThromboGenics NV,Unity Biotechnology Inc,Verseon Corp,Xbrane Biopharma AB

 

Table of Contents

Table of Contents 2

Introduction 5

Diabetic Macular Edema – Overview 6

Diabetic Macular Edema – Therapeutics Development 7

Diabetic Macular Edema – Therapeutics Assessment 18

Diabetic Macular Edema – Companies Involved in Therapeutics Development 27

Diabetic Macular Edema – Drug Profiles 49

Diabetic Macular Edema – Dormant Projects 208

Diabetic Macular Edema – Discontinued Products 211

Diabetic Macular Edema – Product Development Milestones 212

Appendix 222List of Tables

Number of Products under Development for Diabetic Macular Edema, H2 2018

Number of Products under Development by Companies, H2 2018

Number of Products under Development by Companies, H2 2018 (Contd..1), H2 2018

Number of Products under Development by Companies, H2 2018 (Contd..2), H2 2018

Number of Products under Development by Universities/Institutes, H2 2018

Products under Development by Companies, H2 2018

 

 

….Continued

 

 

Thanks for reading this article, you can also get individual chapter wise section or region wise report version like North America, Europe or Asia.

 

Place a Purchase Order for this Market Study (Single User License) at: https://www.htfmarketreport.com/buy-now?format=1&report=1262575

 

Media Contact
Company Name: HTF Market Intelligence Consulting Private Limited
Contact Person: Craig Francis
Email: Send Email
Phone: 2063171218
Address:Unit No. 429, Parsonage Road
City: Edison
State: New Jersey
Country: United States
Website: www.htfmarketreport.com/reports/1262575-diabetic-macular-edema-pipeline-review-4